Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

3.64
-0.0100-0.27%
Post-market: 3.640.00000.00%19:41 EDT
Volume:2.47M
Turnover:9.08M
Market Cap:348.34M
PE:-4.01
High:3.87
Open:3.67
Low:3.58
Close:3.65
52wk High:11.46
52wk Low:1.07
Shares:95.70M
Float Shares:72.51M
Volume Ratio:1.83
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9078
EPS(LYR):-0.9791
ROE:-74.02%
ROA:-44.09%
PB:2.72
PE(LYR):-3.72

Loading ...

Rezolute publishes corporate presentation on ersodetug Phase 3 hyperinsulinism programs

Reuters
·
Apr 01

Rezolute CFO Daron Evans reports purchase of common shares worth $28,500

Reuters
·
Apr 01

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Atara Biotherapeutics (ATRA) and Rezolute (RZLT)

TIPRANKS
·
Mar 30

Rezolute Raised to Outperform From Neutral by Wedbush

Dow Jones
·
Mar 25

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Rezolute (RZLT) and Demant (OtherWILLF)

TIPRANKS
·
Mar 25

Rezolute upgraded to Outperform from Neutral at Wedbush

TIPRANKS
·
Mar 25

H.C. Wainwright Sticks to Their Buy Rating for Rezolute (RZLT)

TIPRANKS
·
Mar 25

Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2

MT Newswires Live
·
Mar 25

Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT)

TIPRANKS
·
Mar 25

BUZZ-Rezolute rises after FDA talks on rare low blood sugar disease drug

Reuters
·
Mar 24

Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint

Dow Jones
·
Mar 24

Rezolute reports FDA meeting outcomes for its Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism

Reuters
·
Mar 24

Rezolute Provides Update on Its Congenital Hyperinsulinism Program Following FDA Meeting

THOMSON REUTERS
·
Mar 24

Rezolute Inc - Expects Program Update in Second Half of 2026

THOMSON REUTERS
·
Mar 24

Rezolute Inc: FDA Encouraged Company to Submit Study Reports and Analysis Datasets for Agency's Independent Evaluation

THOMSON REUTERS
·
Mar 24

Rezolute Inc - FDA Acknowledges Challenges of Behavioral Factors and Smbg Limitations in Congenital Hi Trials

THOMSON REUTERS
·
Mar 24

XOMA Royalty FY 2025 revenue rose 83% to USD 52.15 million

Reuters
·
Mar 18

Rezolute to Participate in Citizens Life Sciences Conference in Miami

Reuters
·
Mar 04

Faruqi & Faruqi Investigates Investor Claims Against Rezolute Inc

Reuters
·
Feb 25

Faruqi & Faruqi Investigates Potential Investor Claims Against Rezolute Inc

Reuters
·
Feb 21